CDC Offers Guidance on 2 vs. 3 Doses of Serogroup B Meningococcal Vaccine — Physician’s First Watch

Medical News |
May 19, 2017

CDC Offers Guidance on 2 vs. 3 Doses of Serogroup B Meningococcal Vaccine

By Kelly Young

Edited by André Sofair, MD, MPH, and William E. Chavey, MD, MS

The CDC has published new recommendations on when to use two or three doses of the MenB-FHbp vaccine (Trumenba) for preventing serogroup B meningococcal disease.

For patients aged 10 to 25 years who are at increased risk for meningococcal disease (e.g., patients with persistent complement component deficiencies or anatomic or functional asplenia, or microbiologists exposed to N. meningitidis), three doses of MenB-FHbp can be given at 0, 1–2, and 6 months. The three-dose series is also recommended during outbreaks of meningococcal disease. (Category A recommendation)

For patients aged 16 to 23 who aren't at increased risk, two doses of the vaccine should be given at 0 and 6 months. (Category B recommendation)

The recommendations, published in MMWR, don't apply to the other serogroup B meningococcal vaccine, known as MenB-4C (Bexsero). The agency doesn't specify a preference of one vaccine over the other, but patients should stick to one type of vaccine for the series. MenB vaccines can be given with other vaccines, but they should be administered at a different anatomic location.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.